Loading...

VANI VIVANI MEDICAL INC Expansion Plans 8-K Filing

VVN

VN

VIVANI MEDICAL INC

(VANI)

2025 8-K

Financial Update

Stock Offering Update

Business Update

Stock Offering Announcement

Spin-off Update

Cortigent Spin-off

Corporate Update

Clinical Announcement

New Stock Agreement

Product Expansion

Investor Meetings

Asset Acquisitions

Collaboration Expansion

Financial Results

Share Purchase Agreement

Financial Update

Financial Results

Conference Presentations

Clinical Trial Approval

Conference Announcement

Positive Results

Financial Results

Announcement of Clinical St...

FDA Clearance for Clinical ...

Earnings Reports

Open Market Sale Agreement

Financial Results

Appointment of Director

Investment Offering

Compliance regained with Na...

Delisting Notice

Departure of Directors

Earnings Reports

Regulatory Update

Annual Meeting of Stockholders

Earnings Reports

Transition Funding Agreemen...

Regulation FD Disclosure

Investor Conferences

External Links:

On September 4, 2025, Vivani Medical, Inc. announced its clinical development plans for NPM-139, a semaglutide implant aimed at chronic weight management for obese and overweight patients. This filing is significant as it outlines new advancements in their product pipeline.

AI Assistant

VIVANI MEDICAL INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.